The switch to infliximab biosimilars

Affiliations

¹ Scientific and Regulatory Management Department, European Medicines Agency, London E14 5EU, UK. Electronic address: richard.vesely@ema.europa.eu.
² Specialised Scientific Disciplines Department, European Medicines Agency, London E14 5EU, UK.

Comment

Richard Veselý et al. Lancet. 2017.

. 2017 Jun 10;389(10086):2266-2268.

doi: 10.1016/S0140-6736(17)31258-8. Epub 2017 May 11.

¹ Scientific and Regulatory Management Department, European Medicines Agency, London E14 5EU, UK. Electronic address: richard.vesely@ema.europa.eu.
² Specialised Scientific Disciplines Department, European Medicines Agency, London E14 5EU, UK.

No abstract available

Comment on

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.